Effects of imidazoline binding site ligands on the growth and viability of clonal pancreatic β-cells
暂无分享,去创建一个
[1] C. A. Ramsden,et al. Affinity isolation of imidazoline binding proteins from rat brain using 5‐amino‐efaroxan as a ligand , 1999, FEBS letters.
[2] A. Noma,et al. The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. , 1998, Biochemical and biophysical research communications.
[3] Dave Kendall,et al. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. , 1998, Trends in pharmacological sciences.
[4] M. Shibuya,et al. Clotrimazole, an Imidazole Antimycotic, Is a Potent Inhibitor of Angiogenesis , 1998, Japanese journal of cancer research : Gann.
[5] F. Ashcroft,et al. Phentolamine block of KATP channels is mediated by Kir6.2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[6] D. Reis,et al. Stimulation of imidazoline receptors inhibits proliferation of human coronary artery vascular smooth muscle cells. , 1997, Hypertension.
[7] C. A. Ramsden,et al. Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with sigma receptors. , 1997, European journal of pharmacology.
[8] G. Bertrand,et al. Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs. , 1997, European journal of pharmacology.
[9] G. Olmos,et al. Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain. , 1996, European journal of pharmacology.
[10] R. Sobecks,et al. Imidazole antifungals Miconazole and Econazole induce apoptosis in mouse lymphoma and human T cell leukemia cells: regulation by Bcl-2 and potential role of calcium. , 1996, Cell death and differentiation.
[11] L. Callado,et al. Increased density of I2-imidazoline receptors in human glioblastomas. , 1996, Neuroreport.
[12] D. Nutt,et al. [3H]2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. , 1996, European journal of pharmacology.
[13] D. Reis,et al. Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation. , 1996, The Journal of pharmacology and experimental therapeutics.
[14] D. V. van Helden,et al. The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. , 1996, Biochemical and biophysical research communications.
[15] D. Nutt,et al. Functional Studies of Specific Imidazoline‐2 Receptor Ligands , 1995, Annals of the New York Academy of Sciences.
[16] G. Pang,et al. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. , 1995, European journal of pharmacology.
[17] B. de Costa,et al. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[18] J. García-Sevilla,et al. Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease , 1993, Neuroscience Letters.
[19] M. Sastre,et al. Opposite Age‐Dependent Changes of α2A‐Adrenoceptors and Nonadrenoceptor [3H]Idazoxan Binding Sites (I2‐Imidazoline Sites) in the Human Brain: Strong Correlation of I2 with Monoamine Oxidase‐B Sites , 1993, Journal of neurochemistry.
[20] H. J. Olverman,et al. [3H]p-aminoclonidine and [3H]idazoxan label different populations of imidazoline sites on rat kidney. , 1993, European journal of pharmacology.
[21] N. Morgan,et al. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non‐adrenoceptor idazoxan binding sites , 1993, British journal of pharmacology.
[22] W. Bowen,et al. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. , 1993, European journal of pharmacology.
[23] Å. Sjöholm. Intracellular signal transduction pathways that control pancreatic β‐cell proliferation , 1992, FEBS letters.
[24] N. Morgan,et al. The α2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells , 1991 .
[25] J. Henquin,et al. Clonidine inhibits ATP‐sensitive K+channels in mouse pancreatic β‐cells , 1991 .
[26] M. Dunne. Block of ATP‐regulated potassium channels by phentolamine and other α‐adrenoceptor antagonists , 1991 .
[27] N. Morgan,et al. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. , 1990, European journal of pharmacology.
[28] D. Langin,et al. [3H]Idazoxan binding at non-α2-adrenoceptors in rabbit adipocyte membranes , 1989 .
[29] G. Molderings. IMIDAZOLINE RECEPTORS : BASIC KNOWLEDGE, RECENT ADVANCES AND FUTURE PROSPECTS FOR THERAPY AND DIAGNOSIS , 1997 .
[30] A. Rémaury,et al. The insulin-secreting cell line, RINm5F, expresses an alpha-2D adrenoceptor and nonadrenergic idazoxan-binding sites. , 1992, The Journal of pharmacology and experimental therapeutics.
[31] P. Ernsberger,et al. A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors , 1992 .
[32] M. Dunne. Block of ATP-regulated potassium channels by phentolamine and other alpha-adrenoceptor antagonists. , 1991, British journal of pharmacology.
[33] J. Wikberg. High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nervous system: description of a putative idazoxan-receptor. , 1989, Pharmacology & toxicology.